ERBB2 and neoplasm: Since the addition of pertuzumab to trastuzumab clearly improves pCR rates in patients with HER2+ eBC with tumours >2 cm and/or node-positive disease, dual anti-HER2 blockade plus chemotherapy is widely considered as the standard of care [2, 3, 5, 9].